Literature DB >> 8455365

Renal interstitial expansion in insulin-dependent diabetes mellitus.

P H Lane1, M W Steffes, P Fioretto, S M Mauer.   

Abstract

Eighty-four patients with insulin-dependent diabetes mellitus had studies of renal function and quantitative renal morphometry including mesangial volume fraction (Vvmes/glom), index of arteriolar hyalinosis, percentage of globally sclerosed glomeruli (%GS), and interstitial volume fraction for total renal cortex (Vvint/T). There was significant correlation among these four parameters, and all four structural parameters correlated with glomerular filtration rate and the log of urinary albumin excretion. Stepwise multiple regression analysis showed that Vvmes/glom and Vvint/T were additive, suggesting that they are partially independent. Arteriolar hyalinosis and %GS did not improve the correlations further. We hypothesize that Vvmes/glom, Vvint/T, arteriolar hyalinosis, and %GS represent multiple but probably interrelated pathologic mechanisms leading to the functional disturbances of diabetic nephropathy. Longitudinal studies of patients with diabetes and studies of patients with diseases producing interstitial expansion in the absence of glomerular disease may help clarify the independent role of interstitial expansion in the kidney disease of diabetes mellitus.

Entities:  

Mesh:

Year:  1993        PMID: 8455365     DOI: 10.1038/ki.1993.95

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  43 in total

1.  Transforming growth factor beta contributes to progressive diabetic nephropathy.

Authors:  W B Reeves; T E Andreoli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Pirfenidone for diabetic nephropathy.

Authors:  Kumar Sharma; Joachim H Ix; Anna V Mathew; Monique Cho; Axel Pflueger; Stephen R Dunn; Barbara Francos; Shoba Sharma; Bonita Falkner; Tracy A McGowan; Michael Donohue; Satish Ramachandrarao; Ronghui Xu; Fernando C Fervenza; Jeffrey B Kopp
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

Review 3.  Anti-fibrosis therapy and diabetic nephropathy.

Authors:  Anil Karihaloo
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

Review 4.  Endothelial dysfunction as a potential contributor in diabetic nephropathy.

Authors:  Takahiko Nakagawa; Katsuyuki Tanabe; Byron P Croker; Richard J Johnson; Maria B Grant; Tomoki Kosugi; Qiuhong Li
Journal:  Nat Rev Nephrol       Date:  2010-11-02       Impact factor: 28.314

5.  Chronological renal resistive index increases related to atherosclerotic factors, and effect of renin-angiotensin system inhibitors.

Authors:  Yoshito Yamaguchi; Fuyuko Akagaki; Aya Nakamori; Toshihiro Sugiura
Journal:  Clin Exp Nephrol       Date:  2018-11-13       Impact factor: 2.801

6.  Profibrotic Circulating Proteins and Risk of Early Progressive Renal Decline in Patients With Type 2 Diabetes With and Without Albuminuria.

Authors:  Katsuhito Ihara; Jan Skupien; Hiroki Kobayashi; Zaipul I Md Dom; Jonathan M Wilson; Kristina O'Neil; Hannah S Badger; Lenden M Bowsman; Eiichiro Satake; Matthew D Breyer; Kevin L Duffin; Andrzej S Krolewski
Journal:  Diabetes Care       Date:  2020-09-04       Impact factor: 19.112

7.  RAGE mRNA expression in the diabetic mouse kidney.

Authors:  F N Ziyadeh; M P Cohen; J Guo; Y Jin
Journal:  Mol Cell Biochem       Date:  1997-05       Impact factor: 3.396

Review 8.  Normoalbuminuric diabetic kidney disease.

Authors:  Chao Chen; Chang Wang; Chun Hu; Yachun Han; Li Zhao; Xuejing Zhu; Li Xiao; Lin Sun
Journal:  Front Med       Date:  2017-07-18       Impact factor: 4.592

9.  The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007.

Authors:  P Fioretto; M L Caramori; M Mauer
Journal:  Diabetologia       Date:  2008-06-05       Impact factor: 10.122

10.  Soybeans ameliolate diabetic nephropathy in rats.

Authors:  Young Eun Choi; Soo Kyung Ahn; Won Taek Lee; Jong Eun Lee; Seung Hwa Park; Bang Bu Yoon; Kyung Ah Park
Journal:  Evid Based Complement Alternat Med       Date:  2008-03-20       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.